Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Eli Lilly and Company
Stemline Therapeutics, Inc.
Bristol-Myers Squibb
Eli Lilly and Company
Inhibrx Biosciences, Inc
Pathos AI, Inc.
Eli Lilly and Company
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Hoffmann-La Roche
Novartis
In8bio Inc.
BeiGene
Atara Biotherapeutics
Kyowa Kirin Co., Ltd.
Revolution Medicines, Inc.
Advanced Accelerator Applications
Isofol Medical AB
Life Molecular Imaging SA
Arno Therapeutics
AVEO Pharmaceuticals, Inc.
BBB-Therapeutics B.V.